Last reviewed · How we verify
NCT02008045
MR Imaging of Perinatal Brain Injury
trial testing Magnetic Resonance Imaging in Perinatal White Matter Brain Injury in 557 participants. Completed in 2 June 2025.
2 June 2025
Quick facts
| Lead sponsor | University of Pittsburgh |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 557 |
| Start date | 1 July 2009 |
| Primary completion | 2 June 2025 |
| Estimated completion | 2 June 2025 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Magnetic Resonance Imaging
- Neurodevelopmental Testing
Conditions studied
- Perinatal White Matter Brain Injury — all drugs for Perinatal White Matter Brain Injury →
Sponsor
University of Pittsburgh
Who can join
Adults 1 Day to 7, any sex, with Perinatal White Matter Brain Injury. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to collect and compare information from cranial ultrasounds, magnetic resonance imaging scans, neurological exam and neuropsychological assessments of children. The investigators hope that the information collected in this study will help with early screening, diagnosis and treatment of brain injury in newborns as well as identify a connection between MR imaging (MRI-magnetic resonance imaging, MRS-magnetic resonance spectroscopy) and neurodevelopmental outcome.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT02008045
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Magnetic Resonance Imaging
Trials testing the same drug.
- NCT03192007 — Multi-Parametric MRI for Renal Transplantation · not yet recruiting
- NCT07229339 — Zipalertinib With Carboplatin and Pemetrexed for the Treatment of Resectable, Stage II-IIIB, Non-Small Cell Lung Cancer · Phase 2 · not yet recruiting
- NCT07441681 — Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive · Phase 3 · not yet recruiting
- NCT07147231 — Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cem · Phase 1, PHASE2 · recruiting
- NCT06448286 — PH Weighted Chemical Exchange Saturation Transfer MRI-Based Surgical Resection to Improve Survival in Patients With Glio · Phase 3 · not yet recruiting
Other University of Pittsburgh trials
Trials by the same sponsor.
- NCT05601206 — Collaborative Care Intervention for Cancer Patients and Their Family Caregivers -LITE · NA · not yet recruiting
- NCT06652815 — Cognition, Metacognition, and Stigma in Patients With Suicidal Ideation · not yet recruiting
- NCT06474286 — Prucalopride for Cognitive Functioning in Schizophrenia · NA · not yet recruiting
- NCT06488469 — Behavioural Problems and Cognition in Children With Hypoglycemia Unawareness in Type-1 Diabetes Mellitus · NA · not yet recruiting
- NCT06652802 — Effectiveness of Nurse-Conducted Brief Intervention (NCBI) Supplemented With Mobile for Preventing Alcohol Use Disorders · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02008045 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Pittsburgh
- Last refreshed: 13 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02008045.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing